AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Immix Biopharma shares surge 13.49% premarket after NXC-201 trial shows 75% complete response rate and 2026 BLA submission planned.
ByAinvest
Monday, Dec 8, 2025 4:32 am ET1min read
Immix Biopharma surged 13.49% in premarket trading following the release of robust Phase 2 clinical trial results for its lead candidate NXC-201 in relapsed/refractory AL Amyloidosis, with a 75% complete response rate and potential for 95% efficacy, as presented at ASH 2025. The data, coupled with a planned $100 million equity financing to fund NXC-201 development and a key hire of a former Chimerix executive as Chief Commercial Officer, reinforced investor confidence in the therapy’s commercial potential and regulatory pathway, including a 2026 Biologics License Application submission.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet